One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Complementarity of Public Health and Medicine — Achieving “the Highest Attainable Standard of Health”
David J. Hunter, M.B., B.S., Sc.D.
doi : 10.1056/nejmp2102550
N Engl J Med 2021; 385:481-484
Contact Tracing for Covid-19 — A Digital Inoculation against Future Pandemics
James O’Connell, M.B., B.Ch., B.A.O., and Derek T. O’Keeffe, M.B., B.Ch., M.D., Ph.D.
doi : 10.1056/nejmp2102256
N Engl J Med 2021; 385:484-487
Keeping Our Promise — Supporting Trainees from Groups That Are Underrepresented in Medicine
Monica B. Vela, M.D., Marshall H. Chin, M.D., M.P.H., and Monica E. Peek, M.D., M.P.H.
doi : 10.1056/nejmp2105270
N Engl J Med 2021; 385:487-489
Establishing Medical Civil Rights
Leonore A. Dluhy, B.A., Brendan Abel, J.D., and Robert G. Dluhy, M.D.
doi : 10.1056/nejmp2104468
N Engl J Med 2021; 385:490-491
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Julian D. Gillmore, M.D., Ph.D., Ed Gane, M.B., Ch.B., Jorg Taubel, M.D., Justin Kao, M.B., Ch.B., Marianna Fontana, M.D., Ph.D., Michael L. Maitland, M.D., Ph.D., Jessica Seitzer, B.S., Daniel O’Connell, Ph.D., Kathryn R. Walsh, Ph.D., Kristy Wood, Ph.D., Jonathan Phillips, Ph.D., Yuanxin Xu, M.D., Ph.D., Adam Amaral, B.A., Adam P. Boyd, Ph.D., Jeffrey E. Cehelsky, M.B.A., Mark D. McKee, M.D., Andrew Schiermeier, Ph.D., Olivier Harari, M.B., B.Chir., Ph.D., Andrew Murphy, Ph.D., Christos A. Kyratsous, Ph.D., Brian Zambrowicz, Ph.D., Randy Soltys, Ph.D., David E. Gutstein, M.D., John Leonard, M.D., Laura Sepp-Lorenzino, Ph.D., and David Lebwohl, M.D.
doi : 10.1056/nejmoa2107454
N Engl J Med 2021; 385:493-502
Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein in tissues, predominantly the nerves and heart. NTLA-2001 is an in vivo gene-editing therapeutic agent that is designed to treat ATTR amyloidosis by reducing the concentration of TTR in serum. It is based on the clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR-Cas9) system and comprises a lipid nanoparticle encapsulating messenger RNA for Cas9 protein and a single guide RNA targeting TTR.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Fr?as, M.D., Melanie J. Davies, M.D., Julio Rosenstock, M.D., Federico C. Pérez Manghi, M.D., Laura Fern?ndez Land?, M.D., Brandon K. Bergman, Pharm.D., Bing Liu, Ph.D., Xuewei Cui, Ph.D., and Katelyn Brown, Pharm.D. for the SURPASS-2 Investigators*
doi : 10.1056/nejmoa2107519
N Engl J Med 2021; 385:503-515
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.
Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock
Rebecca Mathew, M.D., Pietro Di Santo, M.D., Richard G. Jung, Ph.D., Jeffrey A. Marbach, M.B., B.S., Jordan Hutson, M.D., Trevor Simard, M.D., F. Daniel Ramirez, M.D., David T. Harnett, M.D., Anas Merdad, M.B., B.S., Aws Almufleh, M.B., B.S., Willy Weng, M.D., Omar Abdel-Razek, M.D., Shannon M. Fernando, M.D., Kwadwo Kyeremanteng, M.D., M.H.A., Jordan Bernick, M.Sc., George A. Wells, Ph.D., Vincent Chan, M.D., Michael Froeschl, M.D., C.M., Marino Labinaz, M.D., Michel R. Le May, M.D., Juan J. Russo, M.D., and Benjamin Hibbert, M.D., Ph.D.
doi : 10.1056/nejmoa2026845
N Engl J Med 2021; 385:516-525
Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the selection of inotropic agents in clinical practice.
Decompression with or without Fusion in Degenerative Lumbar Spondylolisthesis
Ivar M. Austevoll, M.D., Ph.D., Erland Hermansen, M.D., Ph.D., Morten W. Fagerland, Ph.D., Kjersti Storheim, P.T., Ph.D., Jens I. Brox, M.D., Ph.D., Tore Solberg, M.D., Ph.D., Frode Rekeland, M.D., Eric Franssen, M.D., Clemens Weber, M.D., Ph.D., Helena Brisby, M.D., Ph.D., Oliver Grundnes, M.D., Ph.D., Knut R.H. Algaard, M.D., Tordis B?ker, M.D., Hasan Banitalebi, M.D., Kari Indrekvam, M.D., Ph.D., and Christian Hellum, M.D., Ph.D. for the NORDSTEN-DS Investigators*
doi : 10.1056/nejmoa2100990
N Engl J Med 2021; 385:526-538
In patients with lumbar spinal stenosis and degenerative spondylolisthesis, it is uncertain whether decompression surgery alone is noninferior to decompression with instrumented fusion.
Age-Related Macular Degeneration
Rajendra S. Apte, M.D., Ph.D.
doi : 10.1056/nejmcp2102061
N Engl J Med 2021; 385:539-547
Pneumococcal Empyema
Stephanie S. Cabler, M.D., and David A. Rosen, M.D., Ph.D.
doi : 10.1056/nejmicm2035551
N Engl J Med 2021; 385:548
Neutrophilic Eccrine Hidradenitis
Colleen J. Beatty, M.D., and Erica R. Ghareeb, M.D.
doi : 10.1056/nejmicm2101571
N Engl J Med 2021; 385:e19
Turning Purple with Pain
Thomas W. Fredrick, M.D., Manuel B. Braga Neto, M.D., Ph.D., Daniel O. Johnsrud, M.D., Michael Camilleri, M.D., and Victor G. Chedid, M.D.
doi : 10.1056/nejmcps2105278
N Engl J Med 2021; 385:549-554
Fundamentals of Public Health — A New Perspective Series
Barry R. Bloom, Ph.D., Debra Malina, Ph.D., Genevra Pittman, M.A., Stephen Morrissey, Ph.D., and Eric J. Rubin, M.D., Ph.D.
doi : 10.1056/nejme2110145
N Engl J Med 2021; 385:556-557
Gene Editing — A Cure for Transthyretin Amyloidosis?
Mathew S. Maurer, M.D.
doi : 10.1056/nejme2110557
N Engl J Med 2021; 385:558-559
Breaking New Ground with Incretin Therapy in Diabetes
Katherine R. Tuttle, M.D.
doi : 10.1056/nejme2109957
N Engl J Med 2021; 385:560-561
Audio Interview: Looking Back and Looking Forward — Part 2
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/nejme2112855
N Engl J Med 2021; 385:e25
SARS-CoV-2 Variants in Patients with Immunosuppression
Lawrence Corey, M.D., Chris Beyrer, M.D., M.P.H., Myron S. Cohen, M.D., Nelson L. Michael, M.D., Ph.D., Trevor Bedford, Ph.D., and Morgane Rolland, Ph.D.
doi : 10.1056/nejmsb2104756
N Engl J Med 2021; 385:562-566
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
doi : 10.1056/nejmc2107725
N Engl J Med 2021; 385:567-569
Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study
doi : 10.1056/nejmc2107920
N Engl J Med 2021; 385:570-571
ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant
doi : 10.1056/nejmc2110093
N Engl J Med 2021; 385:571-572
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
doi : 10.1056/nejmc2109509
N Engl J Med 2021; 385:572-574
Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery
doi : 10.1056/nejmc2109676
N Engl J Med 2021; 385:574-575
Gastric Emptying Abnormalities in Diabetes Mellitus
doi : 10.1056/nejmc2109448
N Engl J Med 2021; 385:575-576
